Effect of Rosiglitazone on the Vascular Biology of Human Fat Tissue
Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
Insulin resistance is a common condition that can lead to type 2 diabetes. One of the
commonly prescribed diabetes medications, called rosiglitazone, works by decreasing insulin
resistance. Rosiglitazone appears to work on fat cells. Animal studies suggest that
rosiglitazone may work by increasing blood vessel growth in fat cells. The purpose of this
research is to see if rosiglitazone also increases blood vessel growth in human fat cells.
The investigators will compare results from before and after being on rosiglitazone for 6
weeks.